Remus Pharmaceuticals Limited — PPTs, 20-08-2025: Investor Presentation

Remus Pharma showcased robust FY25 performance, with consolidated revenue soaring ~191% to ₹620.4 Cr and profit after tax up ~58% to ₹38.4 Cr. Operating on an asset-light model, the company excels in niche, off-patent formulations across 40+ semi-regulated global markets. The 2024 acquisition of Espee Global Holdings marked a significant US market entry, specializing in hard-to-access drugs.

Growth drivers include securing first-mover advantage for off-patent products, leveraging regulatory expertise for swift market entry, and expanding its B2C 'Relius' brand. Financial highlights for FY25 include strong RoE of 15.01% and RoCE of 15.69%, with low net debt of 0.05.

Management aims to launch over 200 new B2C products and file 2,000+ new registrations. Strategic expansion targets developed markets organically and via acquisitions, alongside new territories in Eastern Europe, Africa, and ASEAN, further cementing its global footprint.